What is Otek?
Otek belongs to the family of medicines called antibiotics. Otek ophthalmic preparations are used to treat infections of the eye. Otek may be given alone or with other medicines that are taken by mouth for eye infections.
Otek is available only with your doctor's prescription.
Otek indications
Treatment of superficial ocular infections caused by susceptible micro-organisms.,Topical antibacterial agent. this medicine is indicated for the treatment of infected wounds, burns, skin grafts, ulcers, pyoderma, sycosis barbae, impetigo, and in secondarily infected skin lesions of scabies, pediculosis, tinea pedis and contact and allergice dermatitis.
How should I use Otek?
Use Otek as directed by your doctor. Check the label on the medicine for exact dosing instructions.
- Otek is usually administered as an injection at your doctor's office, hospital, or clinic. If you are using Otek at home, carefully follow the injection procedures taught to you by your health care provider.
- If Otek contains particles or is discolored, or if the vial is cracked or damaged in any way, do not use it.
- To clear up your infection completely, continue using Otek for the full course of treatment even if you feel better in a few days.
- Keep this product, as well as syringes and needles, out of the reach of children. Do not reuse needles, syringes, or other materials. Dispose of properly after use. Ask your doctor or pharmacist to explain local regulations for proper disposal.
- If you miss a dose of Otek, use it as soon as possible. Then use your doses at evenly spaced times as directed by your doctor. Do not use 2 doses at once.
Ask your health care provider any questions you may have about how to use Otek.
Uses of Otek in details
Otek is used for the treatment of bacterial infections of the eye surface (conjunctivitis) and eyelids.
Otek description
An antibiotic first isolated from cultures of Streptomyces venequelae in 1947 but now produced synthetically. It has a relatively simple structure and was the first broad-spectrum antibiotic to be discovered. It acts by interfering with bacterial protein synthesis and is mainly bacteriostatic. (From Martindale, The Extra Pharmacopoeia, 29th ed, p106)
Otek dosage
Dosage Forms
Excipient information presented when available (limited, particularly for generics); consult specific product labeling.
Solution Reconstituted,
Intravenous [preservative free]:
Generic: 1 g (1 ea)
Dosing: Adult
Serious infections: IV: 50 to 100 mg/kg/day in divided doses every 6 hours; maximum daily dose: 4 g/day (Moffa 2015).
Dosing: Geriatric
Refer to adult dosing.
Dosing: Pediatric
Note: Follow serum concentrations closely to monitor for toxicity. Use should be restricted to treatment of serious infections when less toxic drugs are ineffective (ie, resistance) or contraindicated. Otek palmitate (oral formulation) is no longer available in the US; Otek sodium succinate (IV formulation) continues to be available.
Meningitis and nonmeningeal pneumococcal infections: Limited data available: Infants, Children, and Adolescents: IV: 18.75 to 25 mg/kg/dose every 6 hours; maximum daily dose: 4,000 mg/day (IDSA [Tunkel 2004]; Kliegman 2020; Red Book [AAP 2018]).
Severe infections: Infants, Children, and Adolescents: IV: 12.5 to 25 mg/kg/dose every 6 hours; maximum daily dose: 4,000 mg/day (Kliegman 2020; Red Book [AAP 2018]; manufacturer labeling).
Otek interactions
Alcohol (Ethyl): Otek (Systemic) may enhance the adverse/toxic effect of Alcohol (Ethyl). Monitor therapy
Barbiturates: Otek (Systemic) may decrease the metabolism of Barbiturates. Barbiturates may increase the metabolism of Otek (Systemic). Monitor therapy
BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). Avoid combination
BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). Avoid combination
BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). Monitor therapy
Carbocisteine: Otek (Systemic) may enhance the adverse/toxic effect of Carbocisteine. Specifically, Otek may enhance adverse effects of alcohol that is present in liquid formulations of carbocisteine-containing products. Monitor therapy
CefTAZidime: Otek (Systemic) may diminish the therapeutic effect of CefTAZidime. Management: Consider using a different combination of antimicrobials, especially if bactericidal activity is desired. If these agents are combined, monitor for reduced antimicrobial effectiveness and/or therapeutic failure. Consider therapy modification
Otek (Ophthalmic): May enhance the adverse/toxic effect of Myelosuppressive Agents. Monitor therapy
Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine. Management: Avoid cholera vaccine in patients receiving systemic antibiotics, and within 14 days following the use of oral or parenteral antibiotics. Avoid combination
Cladribine: May enhance the myelosuppressive effect of Myelosuppressive Agents. Avoid combination
CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased. Monitor therapy
CycloSPORINE (Systemic): Otek (Systemic) may increase the serum concentration of CycloSPORINE (Systemic). Management: Cyclosporine dose reductions will likely be required with initiation of concurrent Otek. Monitor cyclosporine concentrations and response closely following initiation and/or discontinuation of Otek. Consider therapy modification
Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone. Management: Avoid the concomitant use of deferiprone and myelosuppressive agents whenever possible. If this combination cannot be avoided, monitor the absolute neutrophil count more closely. Consider therapy modification
Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased Avoid combination
Fosphenytoin: May decrease the serum concentration of Otek (Systemic). Fosphenytoin may increase the serum concentration of Otek (Systemic). Otek (Systemic) may increase the serum concentration of Fosphenytoin. Monitor therapy
Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. Monitor therapy
Mesalamine: May enhance the myelosuppressive effect of Myelosuppressive Agents. Monitor therapy
Phenytoin: May decrease the serum concentration of Otek (Systemic). Phenytoin may increase the serum concentration of Otek (Systemic). Otek (Systemic) may increase the serum concentration of Phenytoin. Monitor therapy
Promazine: May enhance the myelosuppressive effect of Myelosuppressive Agents. Monitor therapy
RifAMPin: May increase the metabolism of Otek (Systemic). Monitor therapy
Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate. Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic. Consider therapy modification
Sulfonylureas: Otek (Systemic) may decrease the metabolism of Sulfonylureas. Monitor therapy
Tacrolimus (Systemic): Otek (Systemic) may increase the serum concentration of Tacrolimus (Systemic). Management: Tacrolimus dose reductions will likely be required with initiation of concurrent Otek. Monitor tacrolimus concentrations and response closely following initiation and/or discontinuation of Otek. Consider therapy modification
Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected. Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents. Use of this vaccine should be postponed until at least 3 days after cessation of antibacterial agents. Consider therapy modification
Vitamin B12: Otek (Systemic) may diminish the therapeutic effect of Vitamin B12. Monitor therapy
Vitamin K Antagonists (eg, warfarin): Otek (Systemic) may enhance the anticoagulant effect of Vitamin K Antagonists. Otek (Systemic) may increase the serum concentration of Vitamin K Antagonists. Monitor therapy
Voriconazole: Otek (Systemic) may increase the serum concentration of Voriconazole. Monitor therapy
Otek side effects
See also:
What are the possible side effects of Otek?
Allergic reactions following topical application of polymyxin B and bacitracin zinc have rarely been reported.
Anaphylactic reactions have been reported, as rare events, following topical application of zinc bacitracin.
Otek contraindications
See also:
What is the most important information I should know about Otek?
Hypersensitivity to bacitracin, Polymyxins or cross-sensitising substances.
Active ingredient matches for Otek:
| Unit description / dosage (Manufacturer) | Price, USD |
| OTEK EYE DROP 1 packet / 5 ML eye drop each (FDC Ltd) | $ 0.39 |
List of Otek substitutes (brand and generic names): | |
| CETACOL | |
| CETACOL EYE DROP 1 packet / 5 ML eye drop each (Soho) | $ 0.46 |
| CHLORAL | |
| CHLORAL 0.4% EYE DROP 1 packet / 5 ML eye drop each (Alkem Laboratories Ltd) | $ 0.28 |
| Chloral P Eye Drop (Alkem Laboratories Ltd) | $ 0.31 |
| Chloramphenicol Topical | |
| CHLOROCAIN | |
| CHLOROCAIN EAR DROP 1 packet / 15 ML ear drop each (Nri Vision Care Pvt Ltd) | $ 0.29 |
| Ocupol | |
| OCUPOL Eye - Ear Drops / 4mg - 500 I.U. per ml / 5ml units (Praggya (Centaur Pharmaceuticals)) | $ 0.23 |
| Ocupol Polymyxin-B sulphate 10000 IU, Chloramphenicol 10 mg EYE-OINT / 5g (Praggya (Centaur Pharmaceuticals)) | $ 0.28 |
| 5g (Praggya (Centaur Pharmaceuticals)) | $ 0.28 |
| Ocupol Eye 5 gm Ointment (Praggya (Centaur Pharmaceuticals)) | $ 0.05 |
| Ocupol E/E 5 ml Drop (Praggya (Centaur Pharmaceuticals)) | $ 0.06 |
| OCUPOL EYE DROP 1 packet / 5 ML eye drop each (Praggya (Centaur Pharmaceuticals)) | $ 0.54 |
| OCUPOL OINTMENT 1 tube / 5 GM ointment each (Praggya (Centaur Pharmaceuticals)) | $ 0.42 |
| OCUPOL eye oint 5g (Praggya (Centaur Pharmaceuticals)) | $ 0.28 |
| Ocupol Eye Drop (Praggya (Centaur Pharmaceuticals)) | $ 0.54 |
| OPTICHLOR SL | |
| OPTICHLOR SL 1% W/W OINTMENT 1 tube / 5 GM ointment each (Entod Pharmaceuticals Ltd) | $ 0.27 |
| RATCHCURE | |
| RATCHCURE EAR DROP 1 packet / 5 ML ear drop each (Ratchet Biotech Pvt Ltd) | $ 0.82 |
| SENZCLOR | |
| SENZCLOR 1% W/W OINTMENT 1 tube / 5 GM ointment each (Senses Pharmaceuticals Ltd) | $ 0.26 |
References
- DailyMed. "CHLORAMPHENICOL: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
- PubChem. "chloramphenicol". https://pubchem.ncbi.nlm.nih.gov/com... (accessed September 17, 2018).
- DrugBank. "chloramphenicol". http://www.drugbank.ca/drugs/DB00446 (accessed September 17, 2018).
Reviews
The results of a survey conducted on ndrugs.com for Otek are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Otek. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.User reports
Consumer reported useful
No survey data has been collected yetConsumer reported price estimates
No survey data has been collected yet2 consumers reported time for results
To what extent do I have to use Otek before I begin to see changes in my health conditions?As part of the reports released by ndrugs.com website users, it takes 1 day and a few days before you notice an improvement in your health conditions.
Please note, it doesn't mean you will start to notice such health improvement in the same time frame as other users. There are many factors to consider, and we implore you to visit your doctor to know how long before you can see improvements in your health while taking Otek. To get the time effectiveness of using Otek drug by other patients, please click here.
| Users | % | ||
|---|---|---|---|
| 1 day | 2 | 100.0% | |
1 consumer reported age
| Users | % | ||
|---|---|---|---|
| 30-45 | 1 | 100.0% | |
Consumer reviews
There are no reviews yet. Be the first to write one! |
Information checked by Dr. Sachin Kumar, MD Pharmacology
